Date:December 05, 2024
Bio Usawa has a singular focus: to build the manufacturing capacity required to make and supply high quality, effective and affordable antibody-based medicines to the patients who need them. We are applying our 100+ years of combined experience in the industry in close partnership with governments, agencies, educators and health professionals to tap into the talent base for manufacturing these products in Africa, by Africans, for Africans and beyond.
Click here to learn more about our Company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.
As part of the inaugural AORTIC–Bio Usawa Microgrant Program cohort, selected from over 150 applications, we are supporting research that addresses prac…
April 2026The AORTIC–Bio Usawa Microgrant Program was launched to support African researchers addressing serious gaps in cancer care systems. Out of more than 150…
April 2026The inaugural AORTIC–Bio Usawa Microgrant Program brings together a cohort of early- and mid-career researchers, each addressing critical gaps in cancer…
April 2026